Biology subjects

Barille-Nion, S.

Publications and source records attributed to Barille-Nion, S..

3 recordsLinked to original sources

bioRxiv2024

Antimitotic chemotherapy promotes tumor NF-kB secretory phenotype and immunosuppressive CXCR2+ neutrophils chemotaxis in triple-negative breast cancers

Integrated approaches that help understand how tumors, as immune-surveilled ecosystems, respond to chemotherapy are crucial for developing effective antitumor treatments. We previously showed, in immunodeficient context, that antimitotic chemotherapy induced cGAS/STING pathway amplifying antitumor response through a paracrine IFN-1 secretome. We herein studied tumor progression and response to treatment using an immunocompetent murine model. scRNAseq analysis revealed that paclitaxel treatment altered tumor cell phenotypes, favoring tumor cells with a gene expression signature indicative of active NF-{kappa}B pathway with secretory phenotype. Treatment coincidently reduced IFN-I signature cells during tumor progression. The resulting secretory shift correlated with neutrophil recruitment to the tumor, particularly CXCR2+ neutrophils, thereby contributing to an immunosuppressive microenvironment. Pharmacological inhibition of CXCR2 receptor by navarixin reactivated antitumor immunity, enhancing NK cell infiltration and tumor cytotoxicity. Navarixin combination with paclitaxel significantly reduced tumor volume and metastasis. Targeting the NF-{kappa}B-driven secretory phenotype, in particular through neutrophil modulation, holds promise for improving TNBC treatment outcomes.

cancer biology↗

bioRxiv2024

Allosteric regulation of BH3-in-groove interactions by tail anchors of BCL-xL complexes limits BH3 mimetic antagonism.

In briefThe C terminal tail anchors of BCL-2 family proteins exert allosteric influence over the interface crucial for BH3 binding and cell survival. This is regulated by additional features taking place at the mitochondria membrane such as recruitment of the death executioner BAX, which, in response to BH3 binding antagonism, contributes to protein complex disruption. SummaryBCL-xL exerts an essential cell survival function which relies on its hydrophobic groove binding to BH3 domain of BH3-only initiators and downstream BAX/BAK executioners. Combining resonance energy transfer assays and molecular dynamics simulations, we unravel that the C-terminal tail mediated subcellular membrane anchoring of BCL-xL selectively advantages binding to membrane-anchored PUMA initiator over BH3 mimetic ligands of the groove. This is due to the combined allosteric effect on BH3-in-groove binding of BCL-xL and PUMA tail anchors. Moreover, doubly anchored PUMA / BCL-xL complexes recruit endogenous BAX, which favors their antagonism by BH3 mimetics. BAXs C-terminal tail anchor alone is sufficient to enhance BH3 mimetics induced death in cells expressing PUMA / BCL-xL. Thus, the survival function of BCL-xL is regulated by a complex interplay between its tail anchor and those of its interacting partners. This enables both resistance to pharmacological inhibitors and modulation by BAX, which functions as a crucial feedback disruptor of the BCL-xL network. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=80 SRC="FIGDIR/small/616265v1_ufig1.gif" ALT="Figure 1000"> View larger version (12K): org.highwire.dtl.DTLVardef@885687org.highwire.dtl.DTLVardef@e8eeaeorg.highwire.dtl.DTLVardef@8e09fborg.highwire.dtl.DTLVardef@1314d68_HPS_FORMAT_FIGEXP M_FIG C_FIG HighlightsBH3 mimetic antagonism, and subsequent cell death, are limited when full length BCL-xL binds to some membrane-anchored BH3-only proteins such as PUMA. The BH3-in-groove interface is allosterically modulated by tail anchors of PUMA and BCL-xL. Binding to PUMA enriches BCL-xL interactome and recruits BAX. BAX counteracts the effects of tail anchors in BCL-xL complexes.

cell biology↗

bioRxiv2023

NOXA/MCL-1 axis determines cell-death decision between apoptosis and pyroptosis and the inflammatory secretome of breast cancer cells treated with anti-mitotics.

Understanding how the malignant cells respond to chemotherapy is essential to prevent the development of resistance and to improve the efficiency of anti-cancer drugs. Recently, we established that, by intrinsic and paracrine mechanisms, taxol treatment in breast tumor cells increases NOXA a pro-apoptotic protein functioning as an endogenous inhibitor of survival protein MCL-1, thereby enhancing cytotoxic load on the compensatory survival protein BCL-xL. We herein sought to define the contribution of NOXA/MCL-1 to the modality of cell death secretome composition upon anti-mitotic treatment associated with a BCL-xL antagonist. We observed that genetic inactivation of NOXA (enforcing MCL-1 pro-survival activity) in cancer cells not only delays their death when exposed to taxol in combination with the BCL-xL antagonist A1331852, but also alters its morphological characteristics with the apparition of features evoking pyroptosis. We identified the Caspase3-GSDME axis as regulating pyroptotic-like features suggesting that NOXA may act as a negative regulator of this cell death process (and MCL-1 as a positive regulator for it). Furthermore, comparative analysis of secretomes from the NOXA proficient or deficient cancer cells treated by taxol reveals variations in inflammatory cytokine production including those of IL-1{beta} and IL-18. Thus, our results show that anti-mitotic treatments are able to induce death by apoptosis and/or pyroptosis depending on BCL-2 family balance in breast cancer cells. Furthermore, NOXA/MCL-1 ratio appears to control the communication between these two types of cell death and their associated extracellular inflammatory signals in coordination with the pore-forming gasdermin GSDME.

cancer biology↗